Theragnostic Technologies is a seed stage biomedical company focused on high performance multifunctional nanotechnology-enabled materials and devices having ties to Stonybrook University. Describing the firm as working on customizable nano-carrier platforms for next-generation integrated diagnostic & therapeutic medicine, Principals of the firm operate a nano-technology carrier platform intended to undertake R&D involving high performance multifunctional nanotechnology-enabled materials and devices. The initial effort involved development of multifunctional nanotechnology-based products for diagnostic, therapeutic & regenerative medicine. First product ManGraDex was an MRI contrast agent. Services offered included a range of cutting-edge biomedical and healthcare products to improve imaging, therapy and tissue regeneration, enabling medical researchers to generate a diversified product pipeline for diagnostic, therapeutic and regenerative medicine.
